A Research Study Looking at the Comparability (Bioequivalence) of Two Forms of Semaglutide in Two Different Pen-injectors in People With Overweight or Obesity

NCT04187300 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Obesity

Interventions

DRUG: Semaglutide

Sponsor

Novo Nordisk A/S